White Paper

Maximizing The Success Of Your CRO Partnerships Whitepaper

Source: Aptuit, Inc.

It’s certainly true that pharmaceutical companies are under intense pressure to replenish pipelines and reverse a trend in which R&D returns are falling below the costs of capital. These financial pressures, along with the need for cost containment efficiencies and time-to-market improvements, have made outsourcing an increasingly attractive option. And yet based on published statistics, it is clear that the sponsor/CRO model still needs to evolve further to address and reverse these trends.

The demand for clinical and non-clinical outsourcing services is growing steadily—estimated at a nearly 11% compound annual growth rate through 2011. And while the number of molecules in development is increasing, with over 2,900 currently in industry pipelines, the number of new molecules reaching the market remains relatively flat.

As a result of these productivity challenges, new models of partnership are emerging with the industry increasingly seeking and leveraging longer-term, strategic partnerships with CROs. For this approach to be successful, however, both CROs and the pharmaceutical industry must transform in order to create partnerships that will drive gains in productivity, catalyze development cycles, and lead to more effective use of resources.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: